Glivec

Showing 1 of 16 from 16 results
Glivec - Total results - 16
Why did PM Modi agree to give away India’s patent sovereignty to Americans?
India

Why did PM Modi agree to give away India’s patent sovereignty to Americans?

The agreement with the US in the sector will affect India’s sovereignty and the lives of its present and future generations.

Novartis patent row: US 'concerned' over India's patent norms, innovation
Business

Novartis patent row: US 'concerned' over India's patent norms, innovation

Raising questions over innovation climate in India, the US has said the recent decision by India's Supreme Court to prohibit patent of Novartis' cancer drug Glivec could "preclude issuance of a patent" in the country.

Merck vs Glenmark: Another instance of MNC highhandedness
Business

Merck vs Glenmark: Another instance of MNC highhandedness

The court case is an attempt by the Big Pharma to pressure the government to not give marketing approval for generic versions of drugs that have been accorded patent in India.

How the Indian judgment on Novartis will reverberate across the world
World

How the Indian judgment on Novartis will reverberate across the world

A systematic campaign organised by major pharma companies against India is already underway for alleged lack of intellectual property protection.

From Apple to Novartis: Why some patents deserve to die
Business

From Apple to Novartis: Why some patents deserve to die

Patents are meant to be given for genuine inventions. Not for minor tweaks. This is why Novartis lost its case with Glivec.

From Apple to Novartis: Why some patents deserve to die
News & Analysis

From Apple to Novartis: Why some patents deserve to die

Patents are meant to be given for genuine inventions. Not for minor tweaks. This is why Novartis lost its case with Glivec.

Novartis judgment: Let's make research a priority, rest will follow
Business

Novartis judgment: Let's make research a priority, rest will follow

Our academic and research institutions have to make research a priority and the government has to liberally fund them. The bottomline of the Glivec and recent experiences is simple - we should get our priorities right. The rest will fall in place. <br /><br />

Manmohan Singh must learn from the Novartis judgement
India

Manmohan Singh must learn from the Novartis judgement

The Prime Minister should evaluate his support for a free trade agreement with the EU, or at least make it more transparent before it is agreed upon.

Novartis patent case: Five facts about the cancer drug Glivec
Business

Novartis patent case: Five facts about the cancer drug Glivec

Glivec has been a major breakthrough invention of the 20th century for the treatment of cancer. Here are five things you should know about the drug.

Why the rejection of Novartis patent plea is a huge victory for India
Breaking Views

Why the rejection of Novartis patent plea is a huge victory for India

Had Novartis won the case, big pharma would have indulged in reckless “ever-greening” of drugs keeping life-saving drugs out of the reach of most people in India.

Will not invest in R&D of medicines in India: Novartis chairman
Business

Will not invest in R&D of medicines in India: Novartis chairman

Drug major Novartis warned that Supreme Court's rejection of its patent plea for cancer drug Glivec will discourage future innovation in India and pointed out that the company has never been granted an original patent for Glivec in the country.

Novartis patent case: Section 3(d) of Indian Patent Act explained
Business

Novartis patent case: Section 3(d) of Indian Patent Act explained

This section states that inventions that are a mere "discovery" of a "new form" of a "known substance" and do not result in increased efficacy of that substance are not patentable.

Timeline: How Novartis lost a seven-year long battle over Glivec
Business

Timeline: How Novartis lost a seven-year long battle over Glivec

The battle over cancer drug Glivec began in 2006 when the pharmaceutical firm was not granted a patent for the drug.

Full text: SC judgement rejecting Novartis patent plea for Glivec
Business

Full text: SC judgement rejecting Novartis patent plea for Glivec

In a landmark judgement, India's Supreme Court today rejected a patent plea by Swiss drugmaker Novartis AG for cancer drug Glivec, boosting the case for cheaper drugs for life-threatening diseases.

Novartis tanks 7% on losing patent battle over cancer drug Glivec
Investing

Novartis tanks 7% on losing patent battle over cancer drug Glivec

Shares of Novartis India today plunged nearly 7 percent to hit a one-year low level on the BSE, after the Supreme Court dismissed Novartis AG's plea for getting its blood cancer drug patented in India.

Boost for cheaper drugs: SC rejects Novartis patent on Glivec
Business

Boost for cheaper drugs: SC rejects Novartis patent on Glivec

A decision in the seven-year legal battle is keenly awaited by the two most interested parties- big pharma companies and health aid groups - with both sides saying the outcome will set a precedent with far-reaching consequences for the future availability of the drugs.